FDA Accepts Bristol Myers' NDA for Mezigdomide Combo in Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) announced that the FDA has accepted its new drug application for mezigdomide combined with carfilzomib and dexamethasone to treat relapsed or refractory multiple myeloma. The agency assigned a PDUFA date of May 13, 2027.
Tickers: $BMY
Topics: drug approval multiple myeloma